CA3153793A1 - Drug delivery formulations - Google Patents
Drug delivery formulations Download PDFInfo
- Publication number
- CA3153793A1 CA3153793A1 CA3153793A CA3153793A CA3153793A1 CA 3153793 A1 CA3153793 A1 CA 3153793A1 CA 3153793 A CA3153793 A CA 3153793A CA 3153793 A CA3153793 A CA 3153793A CA 3153793 A1 CA3153793 A1 CA 3153793A1
- Authority
- CA
- Canada
- Prior art keywords
- risperidone
- formulation
- days
- administration
- poly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900061P | 2019-09-13 | 2019-09-13 | |
| US62/900,061 | 2019-09-13 | ||
| PCT/IB2020/058474 WO2021048817A1 (en) | 2019-09-13 | 2020-09-11 | Drug delivery formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3153793A1 true CA3153793A1 (en) | 2021-03-18 |
Family
ID=72521677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3153793A Pending CA3153793A1 (en) | 2019-09-13 | 2020-09-11 | Drug delivery formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US12383493B2 (enExample) |
| EP (2) | EP4027973B8 (enExample) |
| JP (2) | JP7661312B2 (enExample) |
| KR (1) | KR20220062372A (enExample) |
| CN (1) | CN114727946A (enExample) |
| AU (2) | AU2020346455B2 (enExample) |
| BR (1) | BR112022004535A2 (enExample) |
| CA (1) | CA3153793A1 (enExample) |
| DK (1) | DK4027973T3 (enExample) |
| ES (1) | ES3058225T3 (enExample) |
| FI (1) | FI4027973T3 (enExample) |
| HR (1) | HRP20251690T1 (enExample) |
| IL (1) | IL291283A (enExample) |
| LT (1) | LT4027973T (enExample) |
| MX (1) | MX2022003051A (enExample) |
| PL (1) | PL4027973T3 (enExample) |
| PT (1) | PT4027973T (enExample) |
| SI (1) | SI4027973T1 (enExample) |
| WO (1) | WO2021048817A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024511353A (ja) * | 2021-03-17 | 2024-03-13 | メドインセルル エス．エー． | リスペリドン及び生分解性ポリマーを含む長時間作用型注射用製剤 |
| JP2026501805A (ja) * | 2023-01-10 | 2026-01-16 | メドインセルル エス．エー． | オランザピン組成物及び使用の方法 |
| WO2026013080A1 (en) | 2024-07-08 | 2026-01-15 | InnoCore Technologies Holding B.V. | Pharmaceutical composition based on biodegradable polymers comprising polyoxazoline |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2299393A1 (en) | 1997-08-08 | 1999-02-18 | Sung Wan Kim | Injectable biodegradable block copolymer gels for use in drug delivery |
| CA2474968A1 (en) | 2002-01-31 | 2003-08-07 | Asahi Techno Glass Corporation | Cryopreservation medium for primate embryo stem cells and cryopreservation method |
| ES2562878T3 (es) | 2007-05-25 | 2016-03-08 | Indivior Uk Limited | Formulaciones de liberación sostenida de compuestos de risperidona |
| BRPI0919465A2 (pt) | 2008-09-30 | 2015-12-01 | Endo Pharmaceuticals Solutions | dispositivo implantável para a liberação de risperidona e métodos de uso do mesmo |
| CN101584652B (zh) | 2009-06-19 | 2012-06-20 | 上海医药集团股份有限公司 | 利培酮缓释凝胶注射剂及其制备方法 |
| US9023897B2 (en) | 2010-12-29 | 2015-05-05 | Medincell | Biodegradable drug delivery compositions |
| US20130144250A1 (en) * | 2011-10-24 | 2013-06-06 | Endo Pharmaceuticals Solutions Inc. | Implantable drug delivery compositions and methods of treatment thereof |
| EP2866837B1 (en) | 2012-06-27 | 2022-12-14 | Medincell S.A. | Biodegradable drug delivery for hydrophobic compositions |
| EA033537B1 (ru) | 2013-03-11 | 2019-10-31 | Durect Corp | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью |
| EP3655017B1 (en) | 2017-07-17 | 2025-01-22 | Medincell S.A. | Pharmaceutical composition |
-
2020
- 2020-09-11 MX MX2022003051A patent/MX2022003051A/es unknown
- 2020-09-11 AU AU2020346455A patent/AU2020346455B2/en active Active
- 2020-09-11 JP JP2022516406A patent/JP7661312B2/ja active Active
- 2020-09-11 DK DK20772437.8T patent/DK4027973T3/da active
- 2020-09-11 CA CA3153793A patent/CA3153793A1/en active Pending
- 2020-09-11 EP EP20772437.8A patent/EP4027973B8/en active Active
- 2020-09-11 CN CN202080077874.0A patent/CN114727946A/zh active Pending
- 2020-09-11 FI FIEP20772437.8T patent/FI4027973T3/fi active
- 2020-09-11 EP EP25212808.7A patent/EP4706658A2/en active Pending
- 2020-09-11 ES ES20772437T patent/ES3058225T3/es active Active
- 2020-09-11 PT PT207724378T patent/PT4027973T/pt unknown
- 2020-09-11 US US17/642,410 patent/US12383493B2/en active Active
- 2020-09-11 LT LTEPPCT/IB2020/058474T patent/LT4027973T/lt unknown
- 2020-09-11 SI SI202030708T patent/SI4027973T1/sl unknown
- 2020-09-11 WO PCT/IB2020/058474 patent/WO2021048817A1/en not_active Ceased
- 2020-09-11 HR HRP20251690TT patent/HRP20251690T1/hr unknown
- 2020-09-11 KR KR1020227012200A patent/KR20220062372A/ko active Pending
- 2020-09-11 PL PL20772437.8T patent/PL4027973T3/pl unknown
- 2020-09-11 BR BR112022004535A patent/BR112022004535A2/pt unknown
-
2022
- 2022-03-10 IL IL291283A patent/IL291283A/en unknown
-
2023
- 2023-12-20 US US18/391,243 patent/US12128132B2/en active Active
-
2025
- 2025-04-02 JP JP2025060885A patent/JP2025106353A/ja active Pending
- 2025-05-12 US US19/205,563 patent/US20250268817A1/en active Pending
- 2025-09-30 AU AU2025242078A patent/AU2025242078A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI4027973T3 (fi) | 2026-01-14 |
| ES3058225T3 (en) | 2026-03-09 |
| JP2025106353A (ja) | 2025-07-15 |
| US20250268817A1 (en) | 2025-08-28 |
| EP4706658A2 (en) | 2026-03-11 |
| PL4027973T3 (pl) | 2026-03-09 |
| EP4027973B8 (en) | 2025-12-17 |
| CN114727946A (zh) | 2022-07-08 |
| LT4027973T (lt) | 2026-01-26 |
| AU2020346455B2 (en) | 2025-07-03 |
| IL291283A (en) | 2022-05-01 |
| WO2021048817A1 (en) | 2021-03-18 |
| US12383493B2 (en) | 2025-08-12 |
| US12128132B2 (en) | 2024-10-29 |
| EP4027973B1 (en) | 2025-11-05 |
| PT4027973T (pt) | 2026-01-05 |
| AU2025242078A1 (en) | 2025-10-23 |
| BR112022004535A2 (pt) | 2022-06-07 |
| SI4027973T1 (sl) | 2026-02-27 |
| HRP20251690T1 (hr) | 2026-02-13 |
| AU2020346455A1 (en) | 2022-03-31 |
| JP2022548616A (ja) | 2022-11-21 |
| DK4027973T3 (da) | 2026-01-12 |
| EP4027973A1 (en) | 2022-07-20 |
| JP7661312B2 (ja) | 2025-04-14 |
| US20240156722A1 (en) | 2024-05-16 |
| MX2022003051A (es) | 2022-06-14 |
| US20220331240A1 (en) | 2022-10-20 |
| KR20220062372A (ko) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12128132B2 (en) | Drug delivery formulations | |
| US20220354956A1 (en) | Biodegradable drug delivery for hydrophobic compositions | |
| JP5847942B2 (ja) | タキサン系活性成分含有液体組成物、その製造方法及び液体製剤 | |
| JP2007515425A (ja) | 医薬組成物 | |
| JP5872551B2 (ja) | パラセタモールを含む医薬組成物およびその製造法 | |
| US12329851B2 (en) | Long acting injectable formulation comprising risperidone and biodegradable polymers | |
| AU2011273064A1 (en) | Pharmaceutical compositions comprising paracetamol and process for preparing the same | |
| BR122025009310A2 (pt) | Formulações de entrega de fármaco | |
| CN116997323A (zh) | 包含利培酮和可生物降解的聚合物的长效可注射制剂 | |
| TWI246927B (en) | One kind of concentrated emulsion containing Paclitaxel (taxane) | |
| ITMI20121154A1 (it) | Soluzione iniettabile di acetaminofene per la somministrazione spinale | |
| OA19944A (en) | Pharmaceutical composition comprising fexofenadine. | |
| HK1208374B (en) | Biodegradable drug delivery for hydrophobic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220526 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240904 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240904 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240904 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D120 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: VOLUNTARY SUBMISSION OF PRIOR ART RECEIVED Effective date: 20240913 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240913 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250225 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250227 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250729 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250729 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251216 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20260114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260120 |